Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison

BackgroundOsimertinib (Osi) has long represented the standard first-line treatment for metastatic EGFR-mutated non-small cell lung cancer. Recently, two randomized phase 3 trials demonstrated that osimertinib plus platinum-based chemotherapy (Osi+CT) and amivamtamab plus lazertinib (Ami+Laz) improve...

Повний опис

Бібліографічні деталі

Автори:	Luna Del Bono, Andrea Ossato, Lorenzo Gasperoni, Stefano Vecchia, Luca Cancanelli, Vera Damuzzo, Stefania Gori, Roberto Tessari, Teodoro Sava, Alessandro Inno
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2026-05-01
Серія:	Frontiers in Oncology
Предмети:	amivantamab EGFR-mutated NSCLC first-line therapy indirect treatment comparison lazertinib network meta-analysis
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1802008/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!